TBX2 and TBX3: The special value for anticancer drug targets

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 2, 2010, Pages 268-274

  Lu, Juan ^a,b   Li, Xiang Ping ^a   Dong, Qi ^b   Kung, Hsiang fu ^b,c   He, Ming Liang ^b,c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Prince of Wales Hospital   (Hong Kong)

Author keywords

TBX2; TBX3; Tumorigenesis

Indexed keywords

BELINOSTAT; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EARLY GROWTH RESPONSE FACTOR 1; FIBRONECTIN; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PCI 24781; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C JUN; PROTEIN MDM2; PROTEIN P107; PROTEIN P53; RETINOBLASTOMA PROTEIN; ROMIDEPSIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBX2; TRANSCRIPTION FACTOR TBX3; TRANSCRIPTION FACTOR TBX5; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VALPROIC ACID; VORINOSTAT; WNT PROTEIN; T BOX TRANSCRIPTION FACTOR;

BREAST CANCER; CARCINOGENESIS; CUTANEOUS T CELL LYMPHOMA; DRUG TARGETING; EMBRYO DEVELOPMENT; GENE EXPRESSION; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIGENE FAMILY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS; T BOX GENE; WNT SIGNALING PATHWAY;

MAMMALIA;

EID: 78649458007     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.07.001     Document Type: Review

References (82)

1. Smith J. T-box genes: what they do and how they do it. Trends Genet. 1999, 15:154-158.
2. He M., Wen L., Campbell C.E., Wu J.Y., Rao Y. Transcription repression by Xenopus ET and its human ortholog TBX3, a gene involved in ulnar-mammary syndrome. Proc. Natl. Acad. Sci. USA 1999, 96:10212-10217.
3. Carreira S., Dexter T.J., Yavuzer U., Easty D.J., Goding C.R. Brachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter. Mol. Cell. Biol. 1998, 18:5099-5108.
4. Dobrovolskaia-Zavadskaia N. Sur la mortification spontanee de la queue che la souris nouveau-nee et sur l'existence d'un caractere (facteur) herediaire "non viable". Crit. Rev. Soc. Biol. 1927, 97:114-116.
5. Herrmann B.G., Labeit S., Poustka A., King T.R., Lehrach H. Cloning of the T gene required in mesoderm formation in the mouse. Nature 1990, 343:617-622.
6. Pflugfelder G.O., Roth H., Poeck B. A homology domain shared between Drosophila optomotor-blind and mouse Brachyury is involved in DNA binding. Biochem. Biophys. Res. Commun. 1992, 186:918-925.
7. Papaioannou V.E., Silver L.M. The T-box gene family. Bioessays 1998, 20:9-19.
8. Agulnik S.I., Garvey N., Hancock S., Ruvinsky I., Chapman D.L., Agulnik I., Bollag R., Papaioannou V., Silver L.M. Evolution of mouse T-box genes by tandem duplication and cluster dispersion. Genetics 1996, 144:249-254.
9. Showell C., Binder O., Conlon F.L. T-box genes in early embryogenesis. Dev. Dyn. 2004, 229:201-218.
10. Bamshad M., Lin R.C., Law D.J., Watkins W.C., Krakowiak P.A., Moore M.E., Franceschini P., Lala R., Holmes L.B., Gebuhr T.C., Bruneau B.G., Schinzel A., Seidman J.G., Seidman C.E., Jorde L.B. Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat. Genet. 1997, 16:311-315.
11. Li Q.Y., Newbury-Ecob R.A., Terrett J.A., Wilson D.I., Curtis A.R., Yi C.H., Gebuhr T., Bullen P.J., Robson S.C., Strachan T., Bonnet D., Lyonnet S., Young I.D., Raeburn J.A., Buckler A.J., Law D.J., Brook J.D. Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Nat. Genet. 1997, 15:21-29.
12. Basson C.T., Bachinsky D.R., Lin R.C., Levi T., Elkins J.A., Soults J., Grayzel D., Kroumpouzou E., Traill T.A., Leblanc-Straceski J., Renault B., Kucherlapati R., Seidman J.G., Seidman C.E. Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat. Genet. 1997, 15:30-35.
13. Abrahams A., Parker M.I., Prince S. The T-box transcription factor Tbx2: its role in development and possible implication in cancer. IUBMB Life 2010, 62:92-102.
14. Abrahams A., Mowla S., Parker M.I., Goding C.R., Prince S. UV-mediated regulation of the anti-senescence factor Tbx2. J. Biol. Chem. 2008, 283:2223-2230.
15. Wilson V., Conlon F.L. The T-box family. Genome Biol. 2006, 3. (REVIEWS3008).
16. Kispert A., Koschorz B., Herrmann B.G. The T protein encoded by Brachyury is a tissue-specific transcription factor. EMBO J. 1995, 14:4763-4772.
17. Ghosh T.K., Packham E.A., Bonser A.J., Robinson T.E., Cross S.J., Brook J.D. Characterization of the TBX5 binding site and analysis of mutations that cause Holt-Oram syndrome. Hum. Mol. Genet. 2001, 10:1983-1994.
18. Lingbeek M.E., Jacobs J.J., van Lohuizen M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J. Biol. Chem. 2002, 277:26120-26127.
19. Conlon F.L., Fairclough L., Price B.M., Casey E.S., Smith J.C. Determinants of T box protein specificity. Development 2001, 128:3749-3758.
20. Müller C.W., Herrmann B.G. Crystallographic structure of the T domain-DNA complex of the Brachyury transcription factor. Nature 1997, 389:884-888.
21. Coll M., Seidman J.G., Müller C.W. Structure of the DNA-bound T-box domain of human TBX3, a transcription factor responsible for ulnar-mammary syndrome. Structure 2002, 10:343-356.
22. Murakami M., Nakagawa M., Olson E.N., Nakagawa O. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc. Natl. Acad. Sci. USA 2005, 102:18034-18039.
23. Kanai F., Marignani P.A., Sarbassova D., Yagi R., Hall R.A., Donowitz M., Hisaminato A., Fujiwara T., Ito Y., Cantley L.C., Yaffe M.B. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 2000, 19:6778-6791.
24. Lamolet B., Pulichino A.M., Lamonerie T., Gauthier Y., Brue T., Enjalbert A., Drouin J. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001, 104:849-859.
25. Wang G.S., Hong C.J., Yen T.Y., Huang H.Y., Ou Y., Huang T.N., Jung W.G., Kuo T.Y., Sheng M., Wang T.F., Hsueh Y.P. Transcriptional modification by a CASK-interacting nucleosome assembly protein. Neuron 2004, 42:113-128.
26. Messenger N.J., Kabitschke C., Andrews R., Grimmer D., Núñez Miguel R., Blundell T.L., Smith J.C., Wardle F.C. Functional specificity of the Xenopus T-domain protein Brachyury is conferred by its ability to interact with Smad1. Dev. Cell 2005, 8:599-610.
27. Singh R., Horsthuis T., Farin H.F., Grieskamp T., Norden J., Petry M., Wakker V., Moorman A.F., Christoffels V.M., Kispert A. Tbx20 interacts with smads to confine tbx2 expression to the atrioventricular canal. Circ. Res. 2009, 105:442-452.
28. Redmond K.L., Crawford N.T., Farmer H., D'Costa Z.C., O'Brien G.J., Buckley N.E., Kennedy R.D., Johnston P.G., Harkin D.P., Mullan P.B. T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene 2010, 29:3252-3262.
29. Carlson H., Ota S., Campbell C.E., Hurlin P.J. A dominant repression domain in Tbx3 mediates transcriptional repression and cell immortalization: relevance to mutations in Tbx3 that cause ulnar-mammary syndrome. Hum. Mol. Genet. 2001, 10:2403-2413.
30. Yarosh W., Barrientos T., Esmailpour T., Lin L., Carpenter P.M., Osann K., Anton-Culver H., Huang T. TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res. 2008, 68:693-699.
31. Sinclair C.S., Adem C., Naderi A., Soderberg C.L., Johnson M., Wu K., Wadum L., Couch V.L., Sellers T.A., Schaid D., Slezak J., Fredericksen Z., Ingle J.N., Hartmann L., Jenkins R.B., Couch F.J. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res. 2002, 62:3587-3591.
32. Adem C., Soderberg C.L., Hafner K., Reynolds C., Slezak J.M., Sinclair C.S., Sellers T.A., Schaid D.J., Couch F., Hartmann L.C., Jenkins R.B. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosom. Cancer 2004, 41:1-11.
33. Jacobs J.J., Keblusek P., Robanus-Maandag E., Kristel P., Lingbeek M., Nederlof P.M., van Welsem T., van de Vijver M.J., Koh E.Y., Daley G.Q., van Lohuizen M. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 2000, 26:291-299.
34. Fan W., Huang X., Chen C., Gray J., Huang T. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res. 2004, 64:5132-5139.
35. Lomnytska M., Dubrovska A., Hellman U., Volodko N., Souchelnytskyi S. Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int. J. Cancer 2006, 118:412-421.
36. Mahlamäki E.H., Bärlund M., Tanner M., Gorunova L., Höglund M., Karhu R., Kallioniemi A. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosom. Cancer 2002, 35:353-358.
37. Duo S., Tiao-Dong T., Lei Z., Wei W., Hong-Li S., Xian-Wei D. Expression and clinical significance of tbx2 in pancreatic cancer. Asian Pac. J. Cancer Prev. 2009, 10:118-122.
38. Hansel D.E., Rahman A., House M., Ashfaq R., Berg K., Yeo C.J., Maitra A. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin. Cancer Res. 2004, 10:6152-6158.
39. Law D.J., Gebuhr T., Garvey N., Agulnik S.I., Silver L.M. Identification, characterization, and localization to chromosome 17q21-22 of the human TBX2 homolog, member of a conserved developmental gene family. Mamm. Genome 1995, 6:793-797.
40. Wu G., Sinclair C., Hinson S., Ingle J.N., Roche P.C., Couch F.J. Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors. Cancer Res. 2001, 61:4951-4955.
41. Bärlund M., Monni O., Kononen J., Cornelison R., Torhorst J., Sauter G., Kallioniemi O.L.L.I.-P., Kallioniemi A. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 2000, 60:5340-5344.
42. Vance K.W., Carreira S., Brosch G., Goding C.R. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 2005, 65:2260-2268.
43. Rodriguez M., Aladowicz E., Lanfrancone L., Goding C.R. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res. 2008, 68:7872-7881.
44. Renard C.A., Labalette C., Armengol C., Cougot D., Wei Y., Cairo S., Pineau P., Neuveut C., de Reyniès A., Dejean A., Perret C., Buendia M.A. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res. 2007, 67:901-910.
45. Lyng H., Brøvig R.S., Svendsrud D.H., Holm R., Kaalhus O., Knutstad K., Oksefjell H., Sundfør K., Kristensen G.B., Stokke T. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 2006, 7:268.
46. Teng H., Davis E., Abrahams A., Mowla S., Parker M.I., Prince S. A role for Tbx2 in the regulation of the alpha2(1) collagen gene in human fibroblasts. J. Cell. Biochem. 2007, 102:618-625.
47. Yin X.J., Xu J.N., Zou C.Q., He F.S., Fang F.D. Genes differentially expressed in human lung fibroblast cells transformed by glycidyl methacrylate. Biomed. Environ. Sci. 2004, 17:432-441.
48. Davis E., Teng H., Bilican B., Parker M.I., Liu B., Carriera S., Goding C.R., Prince S. Ectopic Tbx2 expression results in polyploidy and cisplatin resistance. Oncogene 2008, 27:976-984.
49. Roninson I.B. Tumor cell senescence in cancer treatment. Cancer Res. 2003, 63:2705-2715.
50. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
51. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 1998, 12:2997-3007.
52. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001, 11:S27-S31.
53. Sherr C.J., Weber J.D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 2000, 10:94-99.
54. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55:5187-5190.
55. Waldman T., Lengauer C., Kinzler K.W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996, 381:713-716.
56. Brummelkamp T.R., Kortlever R.M., Lingbeek M., Trettel F., MacDonald M.E., van Lohuizen M., Bernards R. TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J. Biol. Chem. 2002, 277:6567-6572.
57. Carlson H., Ota S., Song Y., Chen Y., Hurlin P.J. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene 2002, 21:3827-3835.
58. Prince S., Carreira S., Vance K.W., Abrahams A., Goding C.R. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res. 2004, 64:1669-1674.
59. Hoogaars W.M., Barnett P., Rodriguez M., Clout D.E., Moorman A.F., Goding C.R., Christoffels V.M. TBX3 and its splice variant TBX3 + exon 2a are functionally similar. Pigment Cell Melanoma Res. 2008, 21:379-387.
60. Mason S.L., Loughran O., La Thangue N.B. p14(ARF) regulates E2F activity. Oncogene 2002, 21:4220-4230.
61. Rocha S., Campbell K.J., Perkins N.D. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol. Cell 2003, 12:15-25.
62. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
63. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12:2245-2262.
64. Ogawa H., Ishiguro K., Gaubatz S., Livingston D.M., Nakatani Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 2002, 296:1132-1136.
65. Rayman J.B., Takahashi Y., Indjeian V.B., Dannenberg J.H., Catchpole S., Watson R.J., te Riele H., Dynlacht B.D. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev. 2002, 16:933-947.
66. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000, 14:2393-2409.
67. Chen P.L., Riley D.J., Chen-Kiang S., Lee W.H. Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proc. Natl. Acad. Sci. USA 1996, 93:465-469.
68. Chen P.L., Riley D.J., Chen Y., Lee W.H. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev. 1996, 10:2794-2804.
69. Nead M.A., Baglia L.A., Antinore M.J., Ludlow J.W., McCance D.J. Rb binds c-Jun and activates transcription. EMBO J. 1998, 17:2342-2352.
70. Vance K.W., Shaw H.M., Rodriguez M., Ott S., Goding C.R. The retinoblastoma protein modulates Tbx2 functional specificity. Mol. Biol. Cell Jun 9 2010.
71. Vormer T.L., Foijer F., Wielders C.L., te Riele H. Anchorage-independent growth of pocket protein-deficient murine fibroblasts requires bypass of G2 arrest and can be accomplished by expression of TBX2. Mol. Cell. Biol. 2008, 28:7263-7273.
72. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
73. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
74. Fong S., Emelyanov A., Teh C., Korzh V. Wnt signalling mediated by Tbx2b regulates cell migration during formation of the neural plate. Development 2005, 132:3587-3596.
75. Schmalhofer O., Brabletz S., Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 28:151-166.
76. Baron V., Adamson E.D., Calogero A., Ragona G., Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006, 13:115-124.
77. Lane A.A., Chabner B.A. Histone Deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
78. Zheng B.J., Guan Y., Hez M.L., Sun H., Du L., Zheng Y., Wong K.L., Chen H., Chen Y., Lu L., Tanner J.A., Watt R.M., Niccolai N., Bernini A., Spiga O., Woo P.C., Kung H.F., Yuen K.Y., Huang J.D. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antivir. Ther. 2005, 10:393-403.
79. Selivanova G., Iotsova V., Okan I., Fritsche M., Ström M., Groner B., Grafström R.C., Wiman K.G. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 1997, 3:632-638.
80. Bonfanti M., Taverna S., Salmona M., D'Incalci M., Broggini M. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 1997, 57:1442-1446.
81. Fåhraeus R., Laín S., Ball K.L., Lane D.P. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene 1998, 16:587-596.
82. Zhou Y., Du W., Koretsky T., Bagby G.C., Pang Q. TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood 2008, 112:2474-2483.